Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 Dec;109(6):NP14-NP20.
doi: 10.1177/03008916231176586. Epub 2023 Jun 2.

Complete pathological response of hormone receptor positive invasive breast cancer in a patient with multiple myeloma treated with ixazomib

Martina Dameri  1 , Alessandro Garlaschi  2 , Paola Cuccarolo  1 , Andrea Ceccardi  1 , Mario Stabile  1 , Irene Valente  3 , Licia Gristina  2 , Massimo Calabrese  2 , Alberto Ballestrero  1   4 , Alberto Tagliafico  2   5 , Gabriele Zoppoli  1   4
Affiliations
Case Reports

Complete pathological response of hormone receptor positive invasive breast cancer in a patient with multiple myeloma treated with ixazomib

Martina Dameri et al. Tumori. 2023 Dec.

Abstract

Multiple myeloma is a hematological cancer characterized by relapse after treatment and poor prognosis. Ixazomib, a second-generation protease inhibitor, is one of the most recently available treatments for relapsed or refractory multiple myeloma, while it has also shown good potential as antitumoral agent in preclinical solid tumor models such as breast cancer cell lines. Here we report the case of a 68-year-old female with multiple myeloma and an incidental cT1b (9 mm) hormone receptor positive breast cancer lesion that showed a complete pathological response to a three-month combination therapy with Ixazomib, bendamustine and dexamethasone and no signs of disease relapse during the later follow-up. This is the first case report describing such clinical outcome in breast cancer following Ixazomib, bendamustine and dexamethasone combination therapy. To investigate the potential antitumoral activity of Ixazomib in breast cancer, we performed in vitro experiments using two hormone receptor positive breast cancer cell lines. We assessed the synergism between Ixazomib and bendamustine and the antiproliferative effect of Ixazomib. We found no synergistic interaction between the two drugs, while Ixazomib alone showed an antiproliferative effect against tumoral cells, suggesting that this drug has been responsible for tumor regression in our case.

Keywords: MCF7; Multiple myeloma; T47D; breast cancer; ixazomib.

PubMed Disclaimer

Conflict of interest statement

Declaration of conflicting interestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
A 18FDG PET/CT (A) demonstrated an abnormal 18FDG uptake in the right breast. Mammography (B) and Ultrasound (C) demonstrated a suspected 9 mm nodule in the upper inner quadrant of the right breast in correspondence of the 18FDG PET/CT finding. 18FDG PET/CT (D) and mammography (E) demonstrated metabolic and radiographic regression of the breast lesion after three-month therapy with IX.
Figure 2.
Figure 2.
Synergy assessment with SynergyFinder 2.0 in MCF7 and T47D cell lines. (A) Dose-response matrix, (B) Synergy distribution with 2D map, (C) Synergy distribution with 3D map.
Figure 3.
Figure 3.
Proliferation inhibition percentage for MCF7 (A) and T47D (B) after 24-hour treatment with increasing concentrations of IX.
See this image and copyright information in PMC

References

    1. Cowan AJ, Green DJ, Kwok M, et al. Diagnosis and management of multiple myeloma: A review. Jama 2022; 327: 464–477. - PubMed
    1. Robak P, Robak T. Bortezomib for the treatment of hematologic malignancies: 15 years later. Drugs R D 2019; 19: 73–92. - PMC - PubMed
    1. National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program. Cancer stat facts: myeloma, https://seer.cancer.gov/statfacts/html/mulmy.html. (2016, accessed 2 November 2017).
    1. Di Lernia G, Leone P, Solimando AG, et al. Bortezomib treatment modulates autophagy in multiple myeloma. J Clin Med 2020; 9: 552. - PMC - PubMed
    1. Carlson JJ, Guzauskas GF, Chapman RH, et al. Cost-effectiveness of drugs to treat relapsed/refractory multiple myeloma in the United States. J Manag Care Spec Pharm 2018; 24: 29-38b. - PMC - PubMed

Publication types

MeSH terms